TY - JOUR
T1 - Predictors of death in adults with duchenne muscular dystrophy-associated cardiomyopathy
AU - Cheeran, Daniel
AU - Khan, Shaida
AU - Khera, Rohan
AU - Bhatt, Anish
AU - Garg, Sonia
AU - Grodin, Justin L.
AU - Morlend, Robert
AU - Araj, Faris G.
AU - Amin, Alpesh A.
AU - Thibodeau, Jennifer T.
AU - Das, Sandeep
AU - Drazner, Mark H.
AU - Mammen, Pradeep P.A.
N1 - Funding Information:
Dr. Mammen is Co-Chair of the AHA Innovative Research Grant Committee (Basic Science 2), a member of the California Institute of Regenerative Medicine Grant Review Committee, a consultant and site Principal Investigator for the OAR/D-OAR Registry (CareDx Inc), a consultant and recipient of a research grant from PhaseBio, and a consultant for Catabasis and HeartWare. The remaining authors have no disclosures to report.
Funding Information:
This study was supported by grants awarded to Drs. Drazner (James M. Wooten Chair in Cardiology provided by the UT Southwestern Medical Center), Khan (Wellstone Clinical Research Fellowship Award), and Mammen (National Institutes of Health Research Grants [R01-HL102478 and U54-AR068791]).
Publisher Copyright:
© 2017 The Authors.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background--Duchenne muscular dystrophy (DMD) is frequently complicated by development of a cardiomyopathy. Despite significant medical advances provided to DMD patients over the past 2 decades, there remains a group of DMD patients who die prematurely. The current study sought to identify a set of prognostic factors that portend a worse outcome among adult DMD patients. Methods and Results--A retrospective cohort of 43 consecutive patients was followed in the adult UT Southwestern Neuromuscular Cardiomyopathy Clinic. Clinical data were abstracted from the electronic medical record to generate baseline characteristics. The population was stratified by survival to time of analysis and compared with characteristics associated with death. The DMD population was in the early 20s, with median follow-up times over 2 years. All the patients had developed a cardiomyopathy, with the majority of the patients on angiotensin-converting enzyme inhibitors (86%) and steroids (56%), but few other guideline-directed heart failure medications. Comparison between the nonsurviving and surviving cohorts found several poor prognostic factors, including lower body mass index (17.3 [14.8-19.3] versus 25.8 [20.8-29.1] kg/m2, P<0.01), alanine aminotransferase levels (26 [18-42] versus 53 [37-81] units/L, P=0.001), maximum inspiratory pressures (13 [0-30] versus 33 [25-40] cmH2O, P=0.03), and elevated cardiac biomarkers (N-terminal pro-brain natriuretic peptide: 288 [72-1632] versus 35 [21-135] pg/mL, P=0.03]. Conclusions--The findings demonstrate a DMD population with a high burden of cardiomyopathy. The nonsurviving cohort was comparatively underweight, and had worse respiratory profiles and elevated cardiac biomarkers. Collectively, these factors highlight a high-risk cardiovascular population with a worse prognosis.
AB - Background--Duchenne muscular dystrophy (DMD) is frequently complicated by development of a cardiomyopathy. Despite significant medical advances provided to DMD patients over the past 2 decades, there remains a group of DMD patients who die prematurely. The current study sought to identify a set of prognostic factors that portend a worse outcome among adult DMD patients. Methods and Results--A retrospective cohort of 43 consecutive patients was followed in the adult UT Southwestern Neuromuscular Cardiomyopathy Clinic. Clinical data were abstracted from the electronic medical record to generate baseline characteristics. The population was stratified by survival to time of analysis and compared with characteristics associated with death. The DMD population was in the early 20s, with median follow-up times over 2 years. All the patients had developed a cardiomyopathy, with the majority of the patients on angiotensin-converting enzyme inhibitors (86%) and steroids (56%), but few other guideline-directed heart failure medications. Comparison between the nonsurviving and surviving cohorts found several poor prognostic factors, including lower body mass index (17.3 [14.8-19.3] versus 25.8 [20.8-29.1] kg/m2, P<0.01), alanine aminotransferase levels (26 [18-42] versus 53 [37-81] units/L, P=0.001), maximum inspiratory pressures (13 [0-30] versus 33 [25-40] cmH2O, P=0.03), and elevated cardiac biomarkers (N-terminal pro-brain natriuretic peptide: 288 [72-1632] versus 35 [21-135] pg/mL, P=0.03]. Conclusions--The findings demonstrate a DMD population with a high burden of cardiomyopathy. The nonsurviving cohort was comparatively underweight, and had worse respiratory profiles and elevated cardiac biomarkers. Collectively, these factors highlight a high-risk cardiovascular population with a worse prognosis.
KW - Cardiac biomarkers
KW - Cardiomyopathy
KW - Duchenne muscular dystrophy
KW - Heart failure therapy
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=85032213533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032213533&partnerID=8YFLogxK
U2 - 10.1161/JAHA.117.006340
DO - 10.1161/JAHA.117.006340
M3 - Article
C2 - 29042427
AN - SCOPUS:85032213533
SN - 2047-9980
VL - 6
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 10
M1 - e006340
ER -